Latest Tapentadol Stories
LAS VEGAS, Jan. 4, 2011 /PRNewswire/ -- CardioVascular BioTherapeutics, Inc. (Pink Sheets: CVBT) today released summary Phase IIa and Phase IIb clinical trial data for CVBT's biological therapy to treat diabetic wounds, CVBT-141B.
NEW YORK, Nov. 7, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc.
Indications include osteoarthritis, chronic lower back pain SILVER SPRING, Md., Nov. 4, 2010 /PRNewswire-USNewswire/ -- The U.S.
SAN CARLOS, Calif., Oct.
SAN CARLOS, Calif., Oct.15 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) presented promising data today from preclinical studies of NKTR-181, a next-generation mu-opioid analgesic candidate with a novel molecular design.
NASHVILLE, Tenn., Oct. 7 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced the publication of data affirming the safety and efficacy of CaldolorÂ® (ibuprofen) Injection in treating fever in critically ill and non-critically ill adults.
RARITAN, N.J., Oct. 4 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today that it received a Complete Response letter from the U.S.
RARITAN, N.J., Sept. 27 /PRNewswire/ -- Phase 3 safety and efficacy data comparing tapentadol extended release (ER) tablets, an investigational pain medication, to placebo in patients with moderate to severe chronic low back pain have been published online by Expert Opinion on Pharmacotherapy.
NASHVILLE, Tenn., Sept. 23 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced that CaldolorÂ® (ibuprofen) Injection is gaining momentum and being approved for use in a growing number of medical facilities across the country. Several key U.S.
MILAN, September 22, 2010 /PRNewswire/ -- After having handled the worldwide launch of tapentadol, the innovative drug for the severe acute pain, Alberto Grua has been appointed Grunenthal Europe and Australia Executive Vice President.
- Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.